Chief Scientific Officer & Technology Executive Recruitment
Helping Biopharmaceutical and Medical Device Companies Recruit Top Chief Scientific Officer (CSO) & Chief Technology Officer (CTO) Talent in the U.S.
In the past 15 years, scientific research has led to groundbreaking discoveries in life sciences. Key advancements like CRISPR-Cas9 have transformed genetic engineering, making precise gene editing possible. This has helped treat genetic disorders and improved agricultural practices.
Another breakthrough is immunotherapy for cancer, including CAR-T cell therapies. These therapies use the body’s immune system to fight cancer, providing new hope for patients. In infectious diseases, direct-acting antivirals have cured hepatitis C, reducing liver cancer and cirrhosis risks.
The development of mRNA vaccines for COVID-19 also revolutionized vaccine technology, showcasing the power of fast drug discovery and development. All these breakthroughs were made possible by scientific leaders with vision and expertise.
Life Science Partner has helped recruit these leaders by finding Chief Scientific Officers (CSO) who can lead scientific research projects and guide drug development from concept to market.
Our recruitment services focus on placing qualified candidates with strong communication skills and a deep understanding of the scientific field.
Brian Berquist, PhD, joined Wheeler Bio as Chief Development Officer (CDO). Based in Oklahoma City, Wheeler Bio offers scalable solutions for the biotechnology industry. They specialize in speeding up the development of therapeutic antibodies.
Dr. Berquist has a PhD in Molecular Medicine and experience in process development and analytical sciences. He will lead Wheeler Bio’s efforts to enhance their product development and ensure compliance with industry standards. His strong track record of successful projects will support Wheeler Bio’s growth.
For more details, visit Brian Berquist.
A Chief Scientific Officer role (CSO) is essential for shaping a company’s research and development (R&D) direction. This role involves overseeing scientific research projects, product development, and ensuring compliance with regulatory standards. The CSO’s strategic vision helps the company move from discovery to market, ensuring drug development aligns with the latest scientific advancements.
The CSO must stay informed about new technologies, scientific trends, and market changes. By anticipating industry shifts, they keep the company competitive and adaptable. Their ability to communicate with diverse teams and industry partners is key to leading scientific research projects that advance healthcare.
Collaboration is a core part of the CSO role. They work closely with R&D teams, research organizations, and regulatory agencies to drive innovation. Effective communication skills are vital, as the CSO must explain complex ideas clearly to stakeholders. This ensures that every project supports both scientific goals and business strategies.
Doris Cully, PhD, joined Cardioxyl Pharmaceuticals as Vice President of Preclinical Development. She has a strong background in biochemistry, cell biology, and cardiovascular research. At Cardioxyl, she leads drug discovery and development for novel heart failure therapies.
Dr. Cully’s experience includes roles at Merck, where she managed early drug development in the cardiovascular space. At Cardioxyl, she focuses on advancing preclinical programs and ensuring that they progress smoothly from discovery to development.
For more details, visit Doris Cully.
The best Chief Scientific Officers (CSOs) have a mix of technical expertise and leadership skills. Here are qualities we look as a Chief Scientific Officer recruiter:
Mark Phelps, PhD, joined Canary Medical as Vice President of Technology Development. Canary Medical develops smart implants with advanced sensor systems for orthopedic and cardiovascular markets. Dr. Phelps previously led R&D for Medtronic and holds a PhD in Electrical Engineering.
In his role, he leads product development for Canary Medical’s new generation of smart implants, ensuring that all innovations meet regulatory and safety standards.
For more details, visit Mark Phelps.
Life Science Partner has over 30 years of experience recruiting Chief Scientific Officers (CSOs). We understand the scientific field and have built an extensive network across life sciences. Our experience helps us match qualified candidates with the right companies, ensuring a strong long-term fit.
We have strong connections with research organizations, academic institutions, and industry leaders. Our executive search is guided by strategic insights into the biopharmaceutical and medical device sectors. Founder Tom Callaway, MD, brings firsthand experience as a biotech entrepreneur, which adds to our ability to find top talent.
We excel at communicating the value of each role to potential candidates. We know how to attract scientific leaders who not only have technical expertise but also share your company’s vision.
Our recruitment process is tailored to your needs, helping you achieve both immediate and long-term goals.
When you work with Life Science Partner, you choose a firm with a proven track record in executive search. We take a personalized approach to every search, ensuring we find leaders who align with your company’s culture and goals. This approach builds long-term success, with lower turnover and strong leadership teams.
Our recruitment services include in-depth interviews, reference checks, and thorough candidate assessments. We don’t just find someone who fits the role—we find someone who fits your vision.
With Life Science Partner, you can be confident that your company will thrive with the right scientific leadership.
Andrew Penman has been appointed as Vice President of Drug Development at Southern Research Institute. He brings a wealth of experience in clinical development from roles at Pfizer and GlaxoSmithKline. At Southern Research, he will oversee new therapies for a variety of diseases.
Dr. Penman’s expertise will help Southern Research accelerate drug discovery and development programs, ensuring compliance with industry regulations and advancing new therapies to market.
For more details, visit Andrew Penman.